Rescue course corticosteroids
Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex of vertebrates, as well as the synthetic analogues of these hormones. Two main classes of corticosteroids, glucocorticoids and mineralocorticoids, are involved in a wide range …
Rescue course corticosteroids could be provided as early as 7 days from the prior dose, if indicated by the clinical scenario. Whether to administer a repeat or rescue course of corticosteroids with preterm prelabor rupture of membranes (PROM) is controversial, and there is insufficient evidence to make a recommendation for or against.
Rescue ACS course was associated with improved respiratory and neonatal outcomes in twin gestations. Further studies are warranted to confirm our findings and better delineate the optimal regimen of rescue ACS in this setting. Rescue antenatal corticosteroids and neonatal outcomes in twin gestation J Matern Fetal Neonatal Med.
This research was presented at the 29th Annual Meeting of the Society for Maternal–Fetal Medicine, San Diego, CA, Jan. 26-31, 2009. Previous studies using repetitive courses of antenatal corticosteroids (ACS) have demonstrated marginal or no benefit and concern over potential risk.
The prenatal administration of corticosteroids to improve fetal pulmonary maturity is a well-known treatment used to reduce the risk of neonatal respiratory distress syndrome. The most beneficial effect of prenatal corticosteroid administration is 24 h to 7 days after completing the administration [24].
Conclusion: Dexamethasone accelerates maturation of fetal lungs, decrease number of neonates with respiratory distress syndrome and improves survival in preterm delivered neonates. Optimal gestational age for use of dexamethasone therapy is 31 to 34 weeks of gestation.
Based on the results of this study and other similar works in this area, it can be concluded that dexamethasone has lower effect on AFI, BPP, and NST indexes respect to betamethasone and for this reason it is more preferred rather than betamethasone.
Antenatal steroids (dexamethasone or betamethasone) can cross the placenta to mature the fetal lung and brain. In the lung, antenatal steroids can decrease the fetal lung fluid through activation of ENaCs, induce the production of surfactant proteins and lipid synthesis, and alter preterm responses to oxidative stress.
Dexamethasone may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:upset stomach.stomach irritation.vomiting.headache.dizziness.insomnia.restlessness.depression.More items...•
6. Response and effectiveness. Peak effects of dexamethasone are reached within 10 to 30 minutes of administration; however, it may take a couple of days before any inflammation is well controlled.
BetamethasoneClinical dataMetabolismLiver CYP3A4Elimination half-life36-54 hoursExcretionKidney (in urine)Identifiers31 more rows
Some types of betamethasone are up to 600 times as potent as hydrocortisone. Both medications are available in various forms, including: Ointments.
Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone sodium phosphate is very soluble in water and is therefore less likely to cause local gastric irritation than corticosteroids which are only slightly soluble.
Corticosteroids are drugs given to women who are at risk of going into labour early. If given within 7 days of birth, they can reduce the chances of lung disease and death in babies. However, many women taking corticosteroids end up giving birth more than 7 days later, and some women end up giving birth at full term.
A single course of corticosteroids is recommended for pregnant women between 24 0/7 weeks and 33 6/7 weeks of gestation, and may be considered for pregnant women starting at 23 0/7 weeks of gestation, who are at risk of preterm delivery within 7 days 1 11 13.
Immature Lungs – Most babies have mature lungs by 36 weeks of gestation. However, since babies develop at different rates, there are exceptions to this. If a mother and her health care provider know that the baby might be coming early, an amniocentesis may be performed to check the maturity level of the lungs.
The administration of antenatal corticosteroids (ACS) to mothers who subsequently deliver prematurely is one of the few obstetric interventions that unequivocally improves outcome in premature babies. 1, 2 Benefits to the newborn include reductions in mortality, respiratory distress syndrome (RDS), and intraventricular hemorrhage (IVH).
We performed a multicenter randomized double-blind placebo-controlled trial to evaluate the impact of a rescue course of antenatal steroids on the incidence of neonatal morbidity and mortality. Study approval was obtained from every participating hospital's institutional review board and all women signed written informed consent.
This multicenter study was performed from May 2003 through February 2008 in 18 private (15) and university (3) medical centers and conducted by investigators from 10 Obstetrix/Pediatrix Medical Group (Sunrise, FL) maternal-fetal medicine practices and 4 other practices staffed by maternal-fetal medicine attending physicians.
There are 2 important clinical questions addressed by this study. The first is whether the use of rescue steroids reduces morbidity and/or mortality in patients who have been previously treated with ACS but who again threaten to deliver before 34 weeks.
The following individuals and institutions participated as investigators and research nurses: primary study coordinator, Diana Abril, RN, BSN; statistical analysis by Anita F. Das, PhD, AxiStat Inc, San Francisco, CA; and data safety monitoring board, Reese Clark, MD, Debra Guinn, MD, and Amy Kelleher, RT.
Betamethasone and dexamethasone are the most widely studied corticosteroids, and they generally have been preferred for antenatal treatment to accelerate fetal organ maturation. Both cross the placenta in their active form and have nearly identical biologic activity.
Because treatment with corticosteroids for less than 24 hours is still associated with significant reduction in neonatal morbidity and mortality, a first dose of antenatal corticosteroids should be administered even if the ability to give the second dose is unlikely, based on the clinical scenario 11 13.
Groups not studied by the Antenatal Late Preterm Steroids trial include women with multiple gestations, women with pregestational diabetes, women who previously had received a course of corticosteroids, and women who gave birth by cesarean at term.
A Cochrane review concluded that although antenatal corticosteroids are beneficial in singleton gestations, further research is required to demonstrate an improvement in outcomes for multifetal gestations 21 12. More recently, a well-designed retrospective cohort study concluded that administration of a complete course of antenatal corticosteroids 1–7 days before birth in twin pregnancies is associated with a clinically significant decrease in neonatal mortality, short-term respiratory morbidity, and severe neurological injury that is similar in magnitude to that observed among singletons 22. Based on the improved outcomes reported in singleton gestations and limited but more recent data on multifetal gestations, unless a contraindication exists, one course of antenatal corticosteroids should be administered to all patients who are between 24 0/7 weeks and 33 6/7 weeks of gestation and at risk of delivery within 7 days, irrespective of fetal number 21 23. In the absence of data, it is reasonable to extend this so that antenatal corticosteroids may be administered for pregnant women starting at 23 0/7 weeks (as discussed in the periviability section), regardless of fetal number.
The concern that corticosteroids may have the potential to adversely affect neurodevelopmental outcomes is largely based on animal data and from studies of multiple course corticosteroids 39. The MFMU study of repeat course corticosteroids suggested that four or more courses may be associated with the development of cerebral palsy 39. However, numerous studies have shown no evidence of long-term harm (and in fact showed improved survival and neurodevelopmental outcomes with long-term pulmonary and other benefits), particularly as it relates to a single course of corticosteroids administered at less than 34 0/7 weeks of gestation 48 12. A follow-up to a trial of antenatal corticosteroids at term (greater than 37 0/7 weeks of gestation) showed a difference in subjective teacher evaluation of a child’s quartile of ability, with more children assessed at less than 25% for performance (17.7% versus 8.5%, P =.03) among those randomized to the corticosteroids but, at the same time, showed no difference in objective neurocognitive outcomes after assessing five neurocognitive dimensions 49. This single signal does not lead us to caution against corticosteroid use, particularly as it refers to term exposure, but continued surveillance of long-term outcomes should be supported. The only data available about long-term neurocognitive outcomes after late preterm administration of antenatal corticosteroids versus placebo come from the initial corticosteroids study 43, where patients at risk of preterm delivery were randomized from 24 0/7 weeks to 35 6/7 weeks of gestation. The 30-year neurodevelopmental follow-up of this cohort were exposed to corticosteroids from 30.9–34.6 weeks of gestation and delivered at a median of 35 weeks of gestation (range 33.4–38.0 weeks of gestation). A total of 34% (n=66) of the cohort delivered at term 50. Cognitive functioning as measured by the Weschler scales, working memory and attention, and other neurocognitive assessments were not different between exposure groups. The MFMU Antenatal Late Preterm Steroids study has not yet obtained long-term outcome data but doing so would add significantly to limited available literature. A final additional consideration regarding corticosteroid risks is that in the context of maternal critical care, antenatal corticosteroids are not contraindicated, even in the setting of sepsis 1 51.